Biogen (BIIB) Income from Continuing Operations (2009 - 2026)

Biogen's Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 319500000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 32.85% year-over-year to 319500000.0; the TTM figure through Mar 2026 stood at 1371900000.0 (down 7.26% YoY), while the FY2025 annual figure was 1292900000.0, down 20.79% from the prior year.
• Income from Continuing Operations was 319500000.0 for Q1 2026 at Biogen, up from 48900000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 1134900000.0 in Q3 2022 to a low of 68300000.0 in Q3 2023.
• Historically, Income from Continuing Operations has averaged 433241176.47 across 5 years, with a median of 388500000.0 in 2024.
• The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations surged 1538.48% in 2022, then tumbled 118.34% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 549500000.0 in 2022, then tumbled by 54.7% to 248900000.0 in 2023, then advanced by 7.15% to 266700000.0 in 2024, then sank by 118.34% to 48900000.0 in 2025, then surged by 753.37% to 319500000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 319500000.0 (Q1 2026), 48900000.0 (Q4 2025), and 466500000.0 (Q3 2025), per Business Quant data.